Overview Mesoblast’s leadership in the development and...

Overview

Mesoblast’s leadership in the development and commercialization of allogeneic cellular medicines is based on its innovative technology platform, proprietary manufacturing processes and multiple Phase 3 assets.Our off-the-shelf product candidates target advanced stages of inflammatory diseases with high, unmet medical needs.

Three product candidates are being evaluated in late-stage development for approval by the United States Food and Drug Administration (“FDA”):

• We have filed a Biologics License Application (“BLA”) to the FDA to seek approval of remestemcel-L for steroid-refractory acute graft versus host disease (“SR-aGVHD”) in children under the brand name RYONCILTM (“RYONCIL”);

• REVASCOR (MPC-150-IM) for advanced heart failure in ongoing Phase 3 clinical trials; and

• MPC-06-ID for chronic low back pain due to degenerative disc disease in ongoing Phase 3 clinical trials.